Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.

Safroneeva, Ekaterina; Vavricka, S R; Fournier, N; Pittet, V; Peyrin-Biroulet, L; Straumann, A; Rogler, G; Schoepfer, A M; Juillerat, Pascal; Swiss IBD Cohort, Study Group (2015). Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Alimentary pharmacology & therapeutics, 42(8), pp. 977-989. Wiley-Blackwell 10.1111/apt.13363

[img] Text
Safroneeva AlimentPharmacolTher 2015_p977.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (423kB) | Request a copy


The impact of early treatment with immunomodulators (IM) and/or TNF antagonists on bowel damage in Crohn's disease (CD) patients is unknown.


To assess whether 'early treatment' with IM and/or TNF antagonists, defined as treatment within a 2-year period from the date of CD diagnosis, was associated with development of lesser number of disease complications when compared to 'late treatment', which was defined as treatment initiation after >2 years from the time of CD diagnosis.


Data from the Swiss IBD Cohort Study were analysed. The following outcomes were assessed using Cox proportional hazard modelling: bowel strictures, perianal fistulas, internal fistulas, intestinal surgery, perianal surgery and any of the aforementioned complications.


The 'early treatment' group of 292 CD patients was compared to the 'late treatment' group of 248 CD patients. We found that 'early treatment' with IM or TNF antagonists alone was associated with reduced risk of bowel strictures [hazard ratio (HR) 0.496, P = 0.004 for IM; HR 0.276, P = 0.018 for TNF antagonists]. Furthermore, 'early treatment' with IM was associated with reduced risk of undergoing intestinal surgery (HR 0.322, P = 0.005), and perianal surgery (HR 0.361, P = 0.042), as well as developing any complication (HR 0.567, P = 0.006).


Treatment with immunomodulators or TNF antagonists within the first 2 years of CD diagnosis was associated with reduced risk of developing bowel strictures, when compared to initiating these drugs >2 years after diagnosis. Furthermore, early immunomodulators treatment was associated with reduced risk of intestinal surgery, perianal surgery and any complication.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Safroneeva, Ekaterina and Juillerat, Pascal


600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services








Doris Kopp Heim

Date Deposited:

09 Feb 2016 15:55

Last Modified:

05 Dec 2022 14:52

Publisher DOI:


PubMed ID:


Additional Information:

Christoph Müller is Member of Swiss IBD Cohort Study Group




Actions (login required)

Edit item Edit item
Provide Feedback